Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma

(2017) Louise Kostos et al.   LEUKEMIA & LYMPHOMA

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes

(2017) Fulvio Massaro et al.   Expert Review of Hematology

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

(2016) Stefanie Groepper et al.   Oncology Research and Treatment

The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells

(2015) Tiziana Tataranni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

(2015) Roberto Latagliata et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

(2015) Massimo Breccia et al.   Expert Review of Hematology

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

(2014) Elena Maria Elli et al.   Mediterranean Journal of Hematology and Infectious Diseases

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

(2013) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

(2013) Hans Tesch et al.   ONKOLOGIE

Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

(2009) Silvana Capalbo et al.   ACTA HAEMATOLOGICA

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy

(2009) Heather A. Leitch et al.   HEMATOLOGICAL ONCOLOGY

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

(2008) E. Messa et al.   ACTA HAEMATOLOGICA